Cover Image
Market Research Report

Cardiac Marker Testing Market by Type (Troponin I & T, CK-MB, Myoglobin, BNP, hsCRP), Product (Reagent, Instrument), Method (Chemiluminescence, ELISA), Disease (Myocardial Infarction, Congestive Heart Failure), Testing - Global Forecast to 2021

Published by MarketsandMarkets Product code 379872
Published Content info 152 Pages
Delivery time: 1-2 business days
Price
Back to Top
Cardiac Marker Testing Market by Type (Troponin I & T, CK-MB, Myoglobin, BNP, hsCRP), Product (Reagent, Instrument), Method (Chemiluminescence, ELISA), Disease (Myocardial Infarction, Congestive Heart Failure), Testing - Global Forecast to 2021
Published: October 24, 2016 Content info: 152 Pages
Description

The global cardiac marker testing market is estimated to grow at a CAGR of 8.8% from 2016 to 2021 to reach USD 3.50 billion by 2021. Factors such as growing incidences of cardiovascular diseases, the rapidly increasing geriatric population, growing funding from public-private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are fueling the growth of the cardiac marker testing market. On the other hand, technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are the key factors limiting the growth of the global cardiac marker testing market.

Based on the type, the troponin I and T type segment is expected to account for the largest share of the global cardiac marker testing market in 2016. The high sensitivity and specificity of troponin I and T in early detection of cardiovascular diseases is stimulating the growth of this type segment. In addition, the long elevation times and rapid prediction of outcomes is also driving the growth of this market.

Geographically, North America commands the largest share of the global cardiac marker testing market in 2016, followed by Europe. The cardiac marker testing market in North America is primarily driven by the increasing incidence of cardiovascular diseases, growing public-private investments, NIH support towards the development of novel cardiac biomarkers, and rising geriatric population.

The global cardiac marker testing market is highly competitive, with a large number of global and local players. As of 2016, the global cardiac marker testing market was dominated by Roche Diagnostics Limited (a subsidiary of F. Hoffman-La Roche Ltd.) (Switzerland), Abbott Laboratories (U.S.), Siemens AG (Germany), Danaher Corporation (U.S.), bioMerieux SA (France), and Alere Inc. (U.S.). Product launches, approvals, and showcases and partnerships and agreements were the major strategies adopted by market players to achieve growth in the cardiac marker testing market.

Research Coverage:

This report studies the cardiac marker testing market based on type, product, disease, and usability. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions

Reasons to Buy the Report:

From an insights perspective, this research report has focused on various levels of analysis-industry trends, market share analysis of top ten players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the cardiac marker testing market, and high-growth regions and countries and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms in garnering greater market shares. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product portfolios and services offered by the major players in the cardiac marker testing market. The report analyzes the cardiac marker testing market based on type, product, disease, and region
  • Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the cardiac marker testing market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various cardiac marker testing systems across geographies
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the cardiac marker testing market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products and services, distribution networks, and manufacturing capabilities of leading players in the cardiac marker testing market
Table of Contents
Product Code: MD 4673

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKETS COVERED
    • 1.3.1. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
      • 2.2.1.1. Key data from secondary sources
    • 2.2.2. PRIMARY RESEARCH
      • 2.2.2.1. Breakdown of primaries
      • 2.2.2.2. Key data from primary sources
  • 2.3. MARKET SIZE ESTIMATION
      • 2.3.1.1. Research methodology: bottom-up approach
      • 2.3.1.2. Research methodology: top-down approach
  • 2.4. MARKET BREAKDOWN AND DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. EVOLUTION
  • 3.3. CURRENT SCENARIO
  • 3.4. FUTURE OUTLOOK
  • 3.5. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. GLOBAL CARDIAC MARKER TESTING MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2016
  • 4.3. CARDIAC MARKER TESTING MARKET SIZE, BY TYPE, 2016 VS. 2021
  • 4.4. CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2016 VS. 2021
  • 4.5. GEOGRAPHICAL SNAPSHOT OF THE CARDIAC MARKER TESTING MARKET, 2016
  • 4.6. LIFE CYCLE ANALYSIS, BY REGION

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Growing incidences of cardiovascular diseases
      • 5.2.1.2. Rapidly increasing geriatric population and the subsequent increase in the burden of heart diseases worldwide
      • 5.2.1.3. Growing funding from public-private organizations for research on cardiac biomarkers
      • 5.2.1.4. Ongoing clinical trials for identification of novel cardiac biomarkers
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Technical problems related to sample collection and storage
      • 5.2.2.2. Issues related to regulatory and reimbursement systems
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Point-of-care testing (POCT) with cardiac biomarkers
      • 5.2.3.2. Emerging markets to offer new growth avenues for market players

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. VALUE CHAIN ANALYSIS
  • 6.3. INDUSTRY TRENDS
    • 6.3.1. ONGOING RESEARCH ON NOVEL CARDIAC BIOMARKERS FOR CARDIOVASCULAR DISEASES
    • 6.3.2. COMBINATION OF VARIOUS CARDIAC BIOMARKERS TO IMPROVE PATIENT MANAGEMENT
    • 6.3.3. DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN ASSAYS
  • 6.4. PORTER'S FIVE FORCES ANALYSIS
    • 6.4.1. THREAT OF NEW ENTRANTS
    • 6.4.2. THREAT OF SUBSTITUTES
    • 6.4.3. BARGAINING POWER OF SUPPLIERS
    • 6.4.4. BARGAINING POWER OF BUYERS
    • 6.4.5. INTENSITY OF COMPETITIVE RIVALRY

7. CARDIAC MARKER TESTING MARKET, BY TYPE

  • 7.1. INTRODUCTION
  • 7.2. TROPONIN I AND T
  • 7.3. CK-MB
  • 7.4. BNP OR NT-PROBNP
  • 7.5. MYOGLOBIN
  • 7.6. HSCRP
  • 7.7. OTHER BIOMARKERS

8. CARDIAC MARKER TESTING MARKET, BY PRODUCT

  • 8.1. INTRODUCTION
  • 8.2. REAGENTS AND KITS
  • 8.3. INSTRUMENTS
    • 8.3.1. CHEMILUMINESCENCE
    • 8.3.2. IMMUNOFLUORESCENCE
    • 8.3.3. ELISA
    • 8.3.4. IMMUNOCHROMATOGRAPHY

9. CARDIAC MARKER TESTING MARKET, BY DISEASE

  • 9.1. INTRODUCTION
  • 9.2. MYOCARDIAL INFARCTION
  • 9.3. CONGESTIVE HEART FAILURE

10. CARDIAC MARKER TESTING MARKET, BY TYPE OF TESTING

  • 10.1. INTRODUCTION
  • 10.2. LABORATORY TESTING
  • 10.3. POINT-OF-CARE TESTING

11. CARDIAC MARKER TESTING MARKET, BY REGION

  • 11.1. INTRODUCTION
  • 11.2. NORTH AMERICA
    • 11.2.1. U.S.
      • 11.2.1.1. Growing prevalence of cardiovascular diseases
      • 11.2.1.2. Increasing public-private investments on cardiac biomarker research
      • 11.2.1.3. Rising geriatric & obese population
      • 11.2.1.4. NIH support for the development of cardiac biomarkers
    • 11.2.2. CANADA
      • 11.2.2.1. Rising incidence of cardiovascular diseases
      • 11.2.2.2. Increasing government investments
  • 11.3. EUROPE
    • 11.3.1. RISING INCIDENCE OF CVD
    • 11.3.2. INCREASING NUMBER OF CONFERENCES AND SYMPOSIUMS
    • 11.3.3. RISING PARTNERSHIPS AND COLLABORATIONS FOR THE DEVELOPMENT OF CARDIAC BIOMARKERS
    • 11.3.4. INCREASING GOVERNMENT INVESTMENTS TO DEVELOP NOVEL CARDIAC BIOMARKERS
  • 11.4. ASIA-PACIFIC
    • 11.4.1. INCREASING INCIDENCE OF CVD
    • 11.4.2. INCREASING AWARENESS DUE TO GOING CONFERENCES AND INITIATIVES TAKEN BY MARKET PLAYERS
    • 11.4.3. GOVERNMENT INVESTMENTS TOWARDS CARDIAC BIOMARKER RESEARCH
  • 11.5. REST OF THE WORLD

12. COMPETITIVE LANDSCAPE

  • 12.1. INTRODUCTION
  • 12.2. STRATEGIC OVERVIEW
  • 12.3. LEADING PLAYERS IN THE CARDIAC MARKER TESTING MARKET
  • 12.4. COMPETITIVE SITUATION AND TRENDS
    • 12.4.1. PRODUCT LAUNCHES, APPROVALS, AND SHOWCASES
    • 12.4.2. AGREEMENTS AND PARTNERSHIPS
    • 12.4.3. ACQUISITIONS
    • 12.4.4. OTHER DEVELOPMENTS

13. COMPANY PROFILES (Overview, Products and Services, Financials, Strategy & Development)*

  • 13.1. INTRODUCTION
  • 13.2. ROCHE DIAGNOSTICS LIMITED (A SUBSIDIARY OF F. HOFFMAN-LA ROCHE LTD.)
  • 13.3. ABBOTT LABORATORIES
  • 13.4. SIEMENS AG
  • 13.5. DANAHER CORPORATION
  • 13.6. BIOMERIEUX SA
  • 13.7. ALERE INC.
  • 13.8. LSI MEDIENCE CORPORATION (A SUBSIDIARY 0F MITSUBISHI CHEMICAL HOLDINGS CORPORATION)
  • 13.9. ORTHO CLINICAL DIAGNOSTICS (A SUBSIDIARY OF THE CARLYLE GROUP)
  • 13.10. RANDOX LABORATORIES LTD.
  • 13.11. GUANGZHOU WONDFO BIOTECH CO., LTD.

*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

14. APPENDIX

  • 14.1. INSIGHTS OF INDUSTRY EXPERTS
  • 14.2. DISCUSSION GUIDE
  • 14.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 14.5. AVAILABLE CUSTOMIZATIONS
  • 14.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 2: CHARACTERISTICS OF TROPONIN CARDIAC MARKER
  • TABLE 3: CARDIAC MARKER TESTING MARKET SIZE FOR TROPONIN I AND T, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 4: NORTH AMERICA: CARDIAC MARKER TESTING MARKET SIZE TROPONIN I AND T, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 5: CHARACTERISTICS OF CK-MB CARDIAC MARKER
  • TABLE 6: CARDIAC MARKER TESTING MARKET SIZE FOR CK-MB, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 7: NORTH AMERICA: CARDIAC MARKER TESTING MARKET SIZE CK-MB, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 8: CARDIAC MARKER TESTING MARKET SIZE FOR BNP OR NT-PROBNP, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 9: NORTH AMERICA: CARDIAC MARKER TESTING MARKET SIZE BNP OR NT-PROBNP, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 10: CHARACTERISTICS OF MYOGLOBIN CARDIAC MARKER
  • TABLE 11: CARDIAC MARKER TESTING MARKET SIZE FOR MYOGLOBIN, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 12: NORTH AMERICA: CARDIAC MARKER TESTING MARKET SIZE FOR MYOGLOBIN, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 13: CUT-OFFS FOR CRP USING STANDARDIZED ASSAY
  • TABLE 14: CARDIAC MARKER TESTING MARKET SIZE FOR HSCRP, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 15: NORTH AMERICA: CARDIAC MARKER TESTING MARKET SIZE FOR HSCRP, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 16: CARDIAC MARKER TESTING MARKET SIZE FOR OTHER BIOMARKERS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 17: NORTH AMERICA: CARDIAC MARKER TESTING MARKET SIZE FOR OTHER BIOMARKERS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 18: CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 19: CARDIAC MARKER TESTING REAGENTS AND KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 20: NORTH AMERICA: CARDIAC MARKER TESTING REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 21: CARDIAC MARKER TESTING INSTRUMENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 22: NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 23: CARDIAC MARKER TESTING INSTRUMENTS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 24: CARDIAC MARKER TESTING INSTRUMENTS MARKET SIZE FOR CHEMILUMINESCENCE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 25: NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET SIZE FOR CHEMILUMINESCENCE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 26: CARDIAC MARKER TESTING INSTRUMENTS MARKET SIZE FOR IMMUNOFLUORESCENCE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 27: NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET SIZE FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 28: CARDIAC MARKER TESTING INSTRUMENTS MARKET SIZE FOR ELISA, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 29: NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET SIZE FOR ELISA, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 30: CARDIAC MARKER TESTING INSTRUMENTS MARKET SIZE FOR IMMUNOCHROMATOGRAPHY, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 31: NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET SIZE FOR IMMUNOCHROMATOGRAPHY, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 32: CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2014-2021 (USD MILLION)
  • TABLE 33: CARDIAC MARKER TESTING MARKET SIZE FOR MYOCARDIAL INFARCTION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 34: NORTH AMERICA: CARDIAC MARKER TESTING MARKET SIZE FOR MYOCARDIAL INFARCTION, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 35: CARDIAC MARKER TESTING MARKET SIZE FOR CONGESTIVE HEART FAILURE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 36: NORTH AMERICA: CARDIAC MARKER TESTING MARKET SIZE FOR CONGESTIVE HEART FAILURE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 37: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2014-2021 (USD MILLION)
  • TABLE 38: CARDIAC MARKER LABORATORY TESTING MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 39: NORTH AMERICA: CARDIAC MARKER LABORATORY TESTING MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 40: CARDIAC MARKER POINT-OF-CARE TESTING MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 41: NORTH AMERICA: CARDIAC MARKER POINT-OF-CARE TESTING MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 42: CARDIAC MARKER TESTING MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 43: NORTH AMERICA: CARDIAC MARKER TESTING MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 44: NORTH AMERICA: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 45: NORTH AMERICA: CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 46: NORTH AMERICA: CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2014-2021 (USD MILLION)
  • TABLE 47: NORTH AMERICA: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2014-2021 (USD MILLION)
  • TABLE 48: U.S.: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 49: U.S.: CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 50: U.S.: CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2014-2021 (USD MILLION)
  • TABLE 51: U.S.: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2014-2021 (USD MILLION)
  • TABLE 52: CANADA: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 53: CANADA: CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 54: CANADA: CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2014-2021 (USD MILLION)
  • TABLE 55: CANADA: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2014-2021 (USD MILLION)
  • TABLE 56: EUROPE: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 57: EUROPE: CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 58: EUROPE: CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2014-2021 (USD MILLION)
  • TABLE 59: EUROPE: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2014-2021 (USD MILLION)
  • TABLE 60: ASIA-PACIFIC: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 61: ASIA-PACIFIC: CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 62: ASIA-PACIFIC: CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2014-2021 (USD MILLION)
  • TABLE 63: ASIA-PACIFIC: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2014-2021 (USD MILLION)
  • TABLE 64: ROW: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 65: ROW: CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 66: ROW: CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2014-2021 (USD MILLION)
  • TABLE 67: ROW: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2014-2021 (USD MILLION)
  • TABLE 68: PRODUCT LAUNCHES, APPROVALS, AND SHOWCASES, 2013-2016
  • TABLE 69: AGREEMENTS AND PARTNERSHIPS, 2013-2016
  • TABLE 70: ACQUISITIONS, 2013-2016
  • TABLE 71: OTHER DEVELOPMENTS, 2013-2016

LIST OF FIGURES

  • FIGURE 1: GLOBAL CARDIAC MARKER TESTING MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: BREAKDOWN OF SUPPLY-SIDE PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: RESEARCH DESIGN
  • FIGURE 4: CARDIAC MARKER TESTING MARKET: DATA TRIANGULATION
  • FIGURE 5: EVOLUTION OF CARDIAC BIOMARKERS
  • FIGURE 6: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE, 2016 VS. 2021 (USD MILLION)
  • FIGURE 7: GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2016 VS. 2021 (USD MILLION)
  • FIGURE 8: GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2016 VS. 2021 (USD MILLION)
  • FIGURE 9: GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2016 VS. 2021 (USD MILLION)
  • FIGURE 10: GLOBAL CARDIAC MARKER TESTING MARKET, BY REGION, 2016
  • FIGURE 11: INCREASING INCIDENCES OF CARDIOVASCULAR DISEASES ACROSS THE GLOBE ARE DRIVING GROWTH IN THE CARDIAC MARKER TESTING MARKET
  • FIGURE 12: TROPONIN I AND T TO DOMINATE THE CARDIAC MARKER TESTING MARKET IN 2016
  • FIGURE 13: REAGENTS AND KITS TO CONTINUE TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
  • FIGURE 14: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 15: ASIA-PACIFIC HOLDS LUCRATIVE GROWTH OPPORTUNITIES
  • FIGURE 16: CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17: CARDIAC MARKER TESTING MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 18: PORTER'S FIVE FORCES ANALYSIS 2016
  • FIGURE 19: CARDIAC MARKER TESTING MARKET SEGMENTATION, BY TYPE
  • FIGURE 20: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE, 2016-2021
  • FIGURE 21: CARDIAC MARKER TESTING MARKET SEGMENTATION, BY PRODUCT
  • FIGURE 22: CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2016 (USD MILLION)
  • FIGURE 23: CARDIAC MARKER TESTING MARKET SEGMENTATION, BY DISEASE
  • FIGURE 24: CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2016 (USD MILLION)
  • FIGURE 25: PREVALENCE OF CONGESTIVE HEART FAILURE, 2014
  • FIGURE 26: CARDIAC MARKER TESTING MARKET SEGMENTATION, BY TYPE OF TESTING
  • FIGURE 27: CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2016 (USD MILLION)
  • FIGURE 28: CARDIAC MARKER TESTING MARKET, BY REGION
  • FIGURE 29: ASIA-PACIFIC TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
  • FIGURE 30: NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT
  • FIGURE 31: EUROPE: CARDIAC MARKER TESTING MARKET SNAPSHOT
  • FIGURE 32: ASIA-PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT
  • FIGURE 33: ROW: CARDIAC MARKER TESTING MARKET SNAPSHOT
  • FIGURE 34: KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2013 TO 2016
  • FIGURE 35: RANK OF KEY PLAYERS IN THE GLOBAL CARDIAC MARKER TESTING MARKET, 2015
  • FIGURE 36: PRODUCT LAUNCHES AND SHOWCASES-MAJORLY ADOPTED GROWTH STRATEGY BY MARKET PLAYERS FROM 2013 TO 2016
  • FIGURE 37: FINANCIAL PERFORMANCE OF THE TOP 6 MARKET PLAYERS IN 2015
  • FIGURE 38: ROCHE DIAGNOSTICS LIMITED: COMPANY SNAPSHOT
  • FIGURE 39: ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • FIGURE 40: SIEMENS AG: COMPANY SNAPSHOT
  • FIGURE 41: DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 42: BIOMERIEUX SA: COMPANY SNAPSHOT
  • FIGURE 43: ALERE INC.: COMPANY SNAPSHOT
  • FIGURE 44: MITSUBISHI CHEMICAL HOLDINGS CORPORATION: COMPANY SNAPSHOT
Back to Top